Member Info for KilkennyTed

And we can drink it on my new boat. Cheers all.

Gizmo your last couple of posts have just been names of Primer design distributors in USA & Canada. Can you expand?

The BJ vaccine sounds very similar to the American.

Updates due on many things @surfie. I wouldn't want to be out when it lands. Lot's to play for as the Government sorts out it's supply chains.
Interesting to se the updates on the care home study.
https://clinicaltrials.gov/ct2/show/study/NCT04453553#contacts
Could be a "Condor Moment"
https://www.youtube.com/watch?v=PPIwFRZXUA4

Polonium. Works every time.

No shame in getting excited about a small rise. Especially mid morning. :)

Keep knocking on 60's door. Will we get in?

News? or FOMO kicked in early

The Tree Shak(e).
When teenage Dylan has cashed in his Nova shares and has all the girls he wants.
Message to mum and dad.
"When the Tree Shak(e)s rocking don't come knocking"
Booooom!!!

gizmo As I see it Novacyt are putting together a Global network, at very high speed. Working with some very big experienced players. They had the product which some of the big boy's want & they have been very clever in getting these colabs together. The question is who is the US distributor??
"In the US, the Company has signed a major distribution agreement for its COVID-19 test with a new global strategic partner. The US is delivering significant sales growth for Novacyt and this new agreement enables the Company to accelerate penetration of its COVID-19 test in this important market. This distribution agreement will focus initially on the US, with the potential to expand into further markets".

CCK It's all guess work at the end of the day. Limited info coming direct from the company so you have to try & "Join up the dot's" . There isn't much bluffing going on so I'm thinking they are holding a good hand.

From Novacyts R&D update
· Development of a two-gene test to address markets employing this testing approach. Launch expected no later than September 2020
· Development, together with a partner, of a serology (antibody) test to detect past infection of COVID-19. Launch expected in Q4 2020

cck I may be wrong but could we be partnering with Bruker on t he 2 gene test & Antibody test.
The following is from a recent Bruker news update. I may be wrong but the wording is very similar form Novacyts recent R&D update.
"In a pilot phase and in collaboration with several partners, Bruker has recently also begun to offer CE-IVD marked serology antibody tests to detect previous COVID-19 infection in selected European countries, as well as a CE-IVD point-of-care (POC) antigen tests to screen for active CV19 infections in under two hours"
https://www.bruker.com/news/bruker-launches-second-generation-fluorotype-sars-cov-2-plus-pcr-test-for-detection-of-sars-cov-2-viral-infections-in-europe.html

The Tree Shake

Let's hope the momentum keeps up. With news, the afterburners will be on.

Can't wait for the next sales update.
Some snippets from the half year update from June. Just a reminder as to why this is such a good investment. IMO

Demand for the Company's COVID-19 test remains strong, with June sales of €25.4 million (£22.5 million) showing the sixth consecutive month of growth. Certain contracts for the supply of the test have also been extended into the second half of the year and in some cases into 2021. With the daily global incidence of SARS-CoV-2 infections continuing to rise, Novacyt expects significant ongoing demand for COVID-19 testing well into 2021.

In the US, the Company has signed a major distribution agreement for its COVID-19 test with a new global strategic partner. The US is delivering significant sales growth for Novacyt and this new agreement enables the Company to accelerate penetration of its COVID-19 test in this important market. This distribution agreement will focus initially on the US, with the potential to expand into further markets.

The Company remains well positioned to address the global need for COVID-19 testing, with its test being sold worldwide. It also has sufficient manufacturing capacity, raw materials and finished goods to meet the expected demand, having orchestrated a significant scale-up of operations during the half year. The Company continues to scale the business internally and has hired 45 people during the first half of the year, with plans to make further investment to strengthen the organisation in the second half of the year.



Development of the Company's COVID-19 test established Novacyt as a pioneer and a leader in COVID-19 diagnostics. Novacyt remains committed to building on this world-class innovative position for COVID-19 testing, and more broadly for respiratory disease testing, and is investing to address unmet needs in the market. Novacyt has already launched three new innovative products, COVID-HT, Exsig™ Direct and Exsig™ Mag, to support laboratories testing for COVID-19. These products are expected to drive incremental revenue and the Company received initial orders in June 2020 following their launch. Novacyt expects to provide an update on its investment in R&D to support continued growth, including a number of new products and innovations to be launched in the near future.



Outlook

Given the visibility of orders, extended contracts and the launch of new COVID-19 related products, the Company anticipates revenue for the second half of the year to be greater than the first half of the year and margins to be at least at a similar level. As a result, there is expected to be greater cash generation in the second half of the year and the Company is reviewing its capital allocation policy to enhance and accelerate long-term value creation through its three-pillar strategy of organic, R&D and acquisitive growth.

322 at mo. Will that do?

Still over 30 mins till close. FOMO has to kick in.

They'll have to move the price up to entice some to sell or take out some limits.

I reckon the fomo bus is just getting warmed up.